about
TNF-alpha inhibitors for psoriatic arthritisDrug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysisHigh early case fatality after ischaemic stroke in Poland: exploration of possible explanations in the International Stroke TrialInfluence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trialPlanning trials in older patients with stroke: data from the International Stroke Trial.Incidence and case fatality rates of first-ever stroke - comparison of data from two prospective population-based studies conducted in Warsaw.Coronary computed tomographic angiography for prediction of procedural and intermediate outcome of bypass grafting to left anterior descending artery occlusion with failed visualization on conventional angiography.The International Stroke Trial databaseValidity of EQ-5D-5L in stroke.Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients.Temporal Changes in the Quality of Acute Stroke Care in Five National Audits across EuropeMeasurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.EQ-5D-5L Polish population normsUse of biologics for psoriasis in Central and Eastern European countries.Lifestyle modification for stroke prevention: facts and fiction.The impact of a belief in life after death on health-state preferences: True difference or artifact?Cost of severe hypoglycaemia in nine European countries.Health outcomes and economic consequences of using angiotensin-converting enzyme inhibitors in comparison with angiotensin receptor blockers in the treatment of arterial hypertension in the contemporary Polish setting.Temporal trends in vascular risk factors and etiology of urban Polish stroke patients from 1995 to 2013.Economic resources consumption structure in severe hypoglycemia episodes: a systematic review and meta-analysis.Effect of prestroke antiplatelets use on first-ever ischaemic stroke severity and early outcome.Variations in acute hospital stroke care and factors influencing adherence to quality indicators in 6 European audits.Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPAA multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey).Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.[Optimal model of comprehensive rehabilitation and secondary prevention].Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.Measurement of Nutritional Status Using Body Mass Index, Waist-to-Hip Ratio, and Waist Circumference to Predict Treatment Outcome in Females and Males with Acute First-Ever Ischemic Stroke.Care for patients after stroke. Results of a two-year prospective observational study from Mazowieckie province in Poland.Comment: The benefits of antiplatelets on stroke--more arguments to keep patients adherent.The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.Acute ischemic stroke care and outcome in centers participating in the Polish National Stroke Prevention and Treatment Registry.Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs associated outcomes in real-world practice - findings from the Polish Hospital Stroke Registry.Pharmacotherapy prior to and in acute ischaemic stroke. The use of pharmacotherapy and drug-associated outcomes in real world practice - findings from the Polish Hospital Stroke Registry.Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.Pheochromocytoma presenting as takotsubo-like cardiomyopathy following delivery.Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry.Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.
P50
Q24240905-DF2D104F-86AF-410E-9BF9-883546081843Q26784192-4D30B135-CA3B-45D5-9DA1-DF1B2D3F7A67Q28193714-41393503-0533-4F3B-A6A8-9C00C01423AAQ28212797-B382580A-52C2-4BA9-96C7-A5733F099C86Q33857355-9271F233-2822-4F91-9E53-541339E5F269Q34002494-BC793C23-C91E-4B6F-8D86-C96421178A73Q34223308-66890976-B80E-456A-9282-15B5A58B18CEQ35014931-A8AA3AA1-17F4-47AD-8B5F-4CB212F94B73Q35197189-988A186E-4670-4C57-A921-54DD6263AB9DQ35687316-B6D64811-48E3-49BE-BBAF-7F66DC743F6DQ36400938-8A0DC07A-27C1-4BBF-8AF3-E7C0DA1AEADFQ37150150-4300CCEF-4031-45AF-BA89-87B5E84CE35DQ37549309-8FE9282B-58C8-4DA1-B6A2-75A23AB067C5Q38586836-BD77A4B8-462E-4E9D-BFF2-94F4897E9233Q38672556-5538E579-2E5D-4B77-AD78-9B21BA37F913Q39573826-02DDCA78-CFFD-4C17-8CD0-1AC60D30570CQ39779773-BFB66C2A-13CD-4A7F-A7D7-68CE73872B3CQ39823209-B74D01A3-4033-4269-9883-391FFF28A109Q40297634-8C1958B8-9387-490B-9E64-794E6CD0661BQ40625945-6E832F5B-1C2F-4200-820E-B9C7E2A99683Q40820113-D4624856-A543-4A63-8DEA-3E42B4EBA586Q41637658-8DBD13F2-9CA5-44B0-8B6F-69764A5FBD3FQ42186235-CDC9A3AB-2836-4584-B8D2-FA7242D81E9FQ43791069-37DCD28D-2351-4156-A0A1-7D7149D1942AQ43926933-9B47DF74-57EB-4A7D-A39C-33491B5B74B0Q44258091-7480D4F9-4900-4535-9A18-5192EE844F87Q45083555-B9FA7726-F3DC-465F-84C2-92650262E92FQ45343238-98A3EAFB-FAF8-4372-80CF-E05E8829C555Q47553245-C0A8D08A-FC56-4EE5-9824-B4B3A87A22BBQ48001555-76C65055-368F-47FB-A670-2531EA07611AQ48130253-30625CA3-2DD5-4C08-B776-D8935718C614Q48333901-278FDFED-348F-45A2-A9D5-0A9BE0E24F94Q48510833-CC9CB41D-E50A-4A2D-80B3-8769BE3BF3CAQ48513356-4FDDAFB2-7052-4249-8D25-367F33B5694AQ50135359-8C12AEC7-792F-4CB5-AA26-5A9E33EEAE34Q50135364-46DC3988-90A2-47CE-9169-4FC864A5B8F3Q50746473-BC5C03A4-CB88-4BAA-8B30-FA721CB3C8ACQ51118629-9F3C2D75-BEEE-46E7-B3A6-023743081424Q51590905-A0D7B329-0DDE-42DF-87F0-1CF8217FBFFFQ53602109-8F8D5AC3-C72D-4896-A969-1D9EAE58AB19
P50
description
researcher ORCID ID = 0000-0002-3730-1996
@en
wetenschapper
@nl
name
Maciej Niewada
@ast
Maciej Niewada
@en
Maciej Niewada
@es
Maciej Niewada
@nl
type
label
Maciej Niewada
@ast
Maciej Niewada
@en
Maciej Niewada
@es
Maciej Niewada
@nl
altLabel
MACIEJ NIEWADA
@en
prefLabel
Maciej Niewada
@ast
Maciej Niewada
@en
Maciej Niewada
@es
Maciej Niewada
@nl
P214
P106
P1153
6602954850
P214
P31
P496
0000-0002-3730-1996
P735
P7859
viaf-250243835